What We Are
Watching

Drug development is becoming a continuously learning system. Most of the ecosystem around it was built for a linear one.

New York just became the first state to halt hyperscale data center construction. History has four precedents for what happens next — and they don't agree with each other.

Private credit is repricing. Mid-market growth strategies built around cheap leverage need to be rethought.

AI infrastructure investment is real. The demand curve being used to justify it deserves more scrutiny than it is getting.

The pace of FDA approvals has accelerated. The manufacturing and supply chain infrastructure has not kept pace.

The opportunity is not in the consumer brands. It is in the platform, the ingredients, and the supply chain infrastructure.

The infrastructure was built for the drug portfolio of a decade ago. The pipeline has moved on.

The healthcare conversation has dominated. The downstream effects on consumer spending are only beginning to surface.

The gap between what is being announced and what will be operational is larger than most supply chain strategies account for.

AI infrastructure demand is creating strategic adjacencies in industries that have nothing to do with software.

Non-invasive BCI is moving from niche to platform. The data layer — not the device — is the strategic asset being built.

Western competitive intelligence tracks R&D investment. It systematically misses deployment pace. That gap is the problem.